Intravenous Aminobisphosphonates for Managing Complications of Malignant Osteolysis in Companion Animals
Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.Topics in Companion Animal Medicine (Impact Factor: 1.41). 09/2009; 24(3):151-6. DOI: 10.1053/j.tcam.2009.02.003
Aminobisphosphonates are a class of drugs effectively used for the management of pathologic skeletal conditions in people, most notably hormonally mediated osteoporosis and cancer-associated bone metastases. Based on their physicochemical properties, aminobisphosphonates concentrate within areas of active skeletal remodeling and exert protective bone biologic effects through the induction of osteoclast apoptosis. Given the similar mineral composition and cellular components of bone tissue shared among mammals, it would be expected that aminobisphosphonates should also be effective in managing malignant bone diseases in dogs and cats. The first half of this review article briefly summarizes the general properties of aminobisphosphonates including their pharmacology, mechanism of action, and potential adverse side effects. The second half of this review focuses on the clinical utility of aminobisphosphonates and measures of response in dogs and cats diagnosed with malignant skeletal tumors.
Conference Paper: Morphological detection algorithm of an event on board a ship[Show abstract] [Hide abstract]
ABSTRACT: In this paper, two novel morphological event detection algorithms are proposed for a vision based warning system, in consideration of a situation such as camera trembling on board a ship. Under such camera trembling, edge-like streaks appear on the difference image and so it is not adequate to use the statistics of the difference image directly for event detection. The proposed algorithms, based on the difference image, exploit morphological filters to sequentially threshold images so as to remove the edge-like components of the difference image, while keeping the vestige of events. The simulation results show a good performance robust to camera trembling
- [Show abstract] [Hide abstract]
ABSTRACT: Minodronate, a new nitrogen-containing bisphosphonate, was developed in Japan. It was the first drug to demonstrate significant prevention of vertebral fractures in Japanese patients with osteoporosis in a phase III doubleblind comparative study. As a result of positive data from clinical trials in Japan minodronate was granted a Japanese marketing approval for the treatment of osteoporosis on January 21, 2009. In vitro studies demonstrated that minodronate is one of the most potent inhibitors of bone resorption among currently available bisphosphonates. Preclinical studies demonstrated the inhibitory effect of minodronate on the decrease in the bone mineral density (BMD) in ovariectomized rats, dogs and monkeys. Daily oral minodronate was safe, well tolerated and effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis. The effects on lumbar and hip BMD and the safety profile of minodronate are comparable to those of alendronate. These data suggest that minodronate is a promising new potent bisphosphonate for the treatment of osteoporosis.
- [Show abstract] [Hide abstract]
ABSTRACT: A 3-year-old Ragdoll cat was referred for investigation of polyuria, polydipsia, vomiting, weight loss and hypercalcaemia. Serum biochemical abnormalities included total and ionised hypercalcaemia and hypophosphataemia. Following clinical investigations a diagnosis of idiopathic hypercalcaemia was made. Because of the severity of the hypercalcaemia and the associated clinical signs, treatment for hypercalcaemia was commenced with pamidronate. Major electrolyte abnormalities were detected but, remarkably, were accompanied by minimal clinical signs. The cat was subsequently treated with oral alendronate and is clinically normal 15 months later. Reports of the use of bisphosphonates in cats are limited and close monitoring of patients is recommended.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.